Holen Sie sich die Stockscreener-App
80.77
1.52%
-1.25
Handel nachbörslich:
80.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$82.02
Offen:
$82.58
24-Stunden-Volumen:
1.89M
Relative Volume:
1.13
Marktkapitalisierung:
$43.59B
Einnahmen:
$9.93B
Nettoeinkommen (Verlust:
$1.12B
KGV:
35.74
EPS:
2.26
Netto-Cashflow:
$1.43B
1W Leistung:
-8.35%
1M Leistung:
-12.07%
6M Leistung:
-11.35%
1J Leistung:
-15.94%
1-Tages-Spanne:
$80.76
$82.77
1-Wochen-Bereich:
$78.11
$90.41
52-Wochen-Spanne:
$78.11
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
80.77 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
ISRG
Intuitive Surgical Inc
|
468.44 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
194.65 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
RMD
Resmed Inc
|
285.77 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
247.07 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Alcon Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:ALC) - Seeking Alpha
Alcon Posts Q2 Revenue Miss on Softer Market Conditions, Earnings Beat on Lower Tax Rate, Needham Says - MarketScreener
Alcon's Q2 Earnings: A Reassessment of Resilience in a Softening Surgical Market - AInvest
Alcon Shares Sink After Cut to Fiscal Year Sales Guidance - MarketScreener
Needham maintains Buy rating on Alcon stock amid market slowdown By Investing.com - Investing.com Australia
Alcon: Soft First-Half Performance Puts Pressure on New Launches to Ramp Up for Remainder of 2025 - Morningstar
Alcon slips 9% on top-line miss, updated 2025 guidance - MSN
Swiss Market Index Rallies; Alcon, Geberit Shares Down - MarketScreener
Tariffs trip Alcon’s expectations - WFMZ.com
European Stocks Drop as US Technology Selloff Dents Sentiment - Bloomberg.com
Alcon stock price target lowered to $92 at BTIG on weaker market growth - Investing.com
Alcon: More Than Meets The Eye (NYSE:ALC) - Seeking Alpha
Alcon: stock slumps after targets reduced - MarketScreener
Why Is Alcon Stock Sinking Wednesday?Alcon (NYSE:ALC) - Benzinga
Transcript : Alcon Inc., Q2 2025 Earnings Call, Aug 20, 2025 - MarketScreener
Earnings call transcript: Alcon Q2 2025 sees EPS beat, stock drops - Investing.com
Alcon : Second Quarter 2025 Earnings Conference Call Press Release - MarketScreener
Alcon’s Strong EPS Performance and Promising Outlook Justify Buy Rating Despite Revenue and EBIT Challenges - TipRanks
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
S&P 500 Futures Decline in Premarket Trading; James Hardie Industries, Alcon Lag - Barron's
Alcon Plunges 12.11% on Tariff Impact, Revenue Warning - AInvest
Needham maintains Buy rating on Alcon stock amid market slowdown - Investing.com
Alcon shares fall after it cuts guidance and warns of tariff impact - Reuters
Alcon’s Stock Drops On Lower Revenue Outlook Despite Earnings Beat - Finimize
Alcon slides over 11% on US tariff impact - breakingthenews.net
Alcon Q2 Core Earnings, Sales Rise; Lowers Full-Year Revenue Outlook; Shares Slump Premarket - MarketScreener
Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit - MSN
Alcon Inc. shares fall 10.31% in premarket after lowering 2025 sales forecast and reporting weak Q2 earnings. - AInvest
Alcon cuts 2025 net sales outlook on tariff pressures - MSN
Alcon trims guidance, sees $100 mln hit from U.S. tariffs - Investing.com
Alcon Q2 2025 slides: Announces $1.5B STAAR acquisition amid softening growth - Investing.com
Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics - sharewise.com
Alcon's Q2 2025 Earnings: Navigating Revenue Softness While Cementing Long-Term Resilience - AInvest
Alcon Reports Higher H1 Net Income and Sales with Strong Global Presence - AInvest
Alcon Posts Higher H1 Net Income, Sales - MarketScreener
Alcon's Q2 2025 Earnings: Navigating Soft Markets and Strategic Expansion - AInvest
Alcon Posts Q2 Loss Amid Revenue Dip; Market Response Signals Mixed Momentum - AInvest
Alcon AG reports results for the quarter ended June 30Earnings Summary - TradingView
Alcon Lifts Earnings Guidance But Falls Short On Revenue - Finimize
Alcon's Q2 Performance and Strategic Challenges: Navigating a Revised Outlook in a Competitive Landscape - AInvest
Alcon’s Strategic Moves: Q2 2025 Results and STAAR Acquisition - TipRanks
Alcon reports Q2 sales up 4% to $2.6 billion, launches new eye treatment - Investing.com
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical - Placera.se
Alcon Reports $287 Million Returned to Shareholders in Q2, Including $121 Million of Stock Repurchases - MarketScreener
Earnings Flash: (ALC) Alcon Q2 Revenue $2.58 Billion Vs. FactSet Est. $2.64 Billion - MarketScreener
Earnings Flash: (ALC) Alcon Q2 Core EPS $0.76 Vs. FactSet Est. $0.73 - MarketScreener
Alcon Q2 Core Earnings, Net Sales Rise; 2025 Revenue Outlook Lowered - MarketScreener
Alcon reports second-quarter 2025 results - MarketScreener
Alcon's Innovation Edge in Cataract Care: A Strategic Catalyst for Growth in Aging Asia-Pacific Markets - AInvest
Alcon's Dominance in Cataract Surgery Innovation and Market Expansion - AInvest
Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS - Stock Titan
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):